Keyphrases
Hepatocellular Carcinoma
100%
Vascular Endothelial Growth Factor Inhibitors
100%
Cardiovascular Adverse Events
100%
Confidence Interval
75%
Tyrosine Kinase Inhibitor
75%
Bevacizumab
75%
Subdistribution Hazard Ratio
62%
Major Adverse Cardiovascular Events
50%
Lenvatinib
37%
Risk Factors
25%
Antiangiogenic
25%
Sorafenib
25%
Adverse Effects
12%
High Risk
12%
Hazard Ratio
12%
Hypertension
12%
Adult Patients
12%
Comorbidity
12%
Cardiovascular Risk
12%
Liver Transplantation
12%
First-line Therapy
12%
Tobacco Use
12%
Academic Medical Centers
12%
Cumulative Incidence
12%
Cardiovascular Events
12%
Portal Vein Thrombosis
12%
Adverse Risk
12%
Advanced Hepatocellular Carcinoma
12%
Therapy Types
12%
Metastatic Hepatocellular Carcinoma
12%
Community Cancer Center
12%
VEGF Inhibitors
12%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Adverse Event
100%
Vasculotropin Inhibitor
100%
Bevacizumab
75%
Protein Tyrosine Kinase Inhibitor
75%
Cardiovascular Disease
50%
Lenvatinib
37%
Antiangiogenic
25%
Sorafenib
25%
Cohort Study
12%
Malignant Neoplasm
12%
Cardiovascular Risk
12%
Portal Vein Thrombosis
12%
Patient History of Liver Transplantation
12%
Comorbidity
12%